Compare · SERM
Enclomiphene vs Raloxifene
Both are serm compounds. Here's how they line up on the evidence — graded the same way.
| Enclomiphene | Raloxifene | |
|---|---|---|
| Evidence | 8/10 | 10/10 |
| Class | SERM | SERM |
| Summary | Enclomiphene is the anti-estrogenic isomer of clomiphene — a selective estrogen receptor modulator (SERM), not a peptide. Human trials consistently show it raises testosterone while preserving fertility, but it is NOT FDA-approved for any use, is available only via off-label compounding, and is banned in sport at all times. | Raloxifene is a selective estrogen receptor modulator (SERM) — an FDA-approved postmenopausal osteoporosis and breast-cancer-risk-reduction drug, not a peptide. Its defining serious risks are blood clots and fatal stroke; it is banned in sport at all times (WADA S4.2). |
| Full profile → | Full profile → |
Enclomiphene
Enclomiphene gets passed around fitness and "research chemical" circles as if it were a peptide or a sleek new-generation drug. It is neither. It is one of the two halves (isomers) that make up clomiphene — specifically the anti-estrogen half — and it is a small-molecule pill in a drug family…
Raloxifene
Raloxifene, sold as Evista, is a pill taken once a day. It belongs to a group of drugs called SERMs — selective estrogen receptor modulators (medicines that switch estrogen's effects on or off depending on which part of the body they reach). It's a legitimate, well-studied prescription drug. It…